IP Library Granted Patent US 10,047,136
Granted Patent B2
US 10,047,136 · App. 15/688,983 · Granted Aug 14, 2018

Consumable cryopreserved cells transiently overexpressing gene(s) encoding drug transporter protein(s)

Inventors: Na Li (Winchester, MA); Jie Wang (Winchester, MA); Christopher J. Patten (Scituate, MA)
Assignee: Corning Incorporated
C07K14/705A01N1/021A01N1/0284C12N5/00C12N5/067C12N5/069C12N15/85G01N33/5008C12N2510/00G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,136
App. No.
15/688,983
Granted
Aug 14, 2018
Kind
B2
Abstract

The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.

Claims (11)

1. A cryopreserved recombinant cell comprising one or more transiently overexpressed genes encoding a drug transporter protein, wherein activity of the drug transporter protein is detectable in a population of the cryopreserved recombinant cell following thaw from cryopreservation, wherein the cryopreserved recombinant cell is transiently transfected with the one or more genes by a method comprising electroporation, and wherein said one or more genes is OAT3 and wherein said cell is HEK293.

2. The recombinant cell of claim 1 , wherein said one or more genes is derived individually from human or an animal species selected from mouse, rat, guinea pigs, dog, and monkey.

3. The recombinant cell of claim 1 , wherein activity of the drug transporter protein is detectable in a population of said cell at least 24 hours post plating following thaw from cryopreservation.

4. The recombinant cell of claim 1 , wherein activity of the drug transporter protein is detectable in a population of said cell at least 48 hours post plating following thaw from cryopreservation.

5. The recombinant cell of claim 1 , wherein activity of the drug transporter protein is detectable in a population of said cell at least 72 hours post plating following thaw from cryopreservation.

6. A process of preparing cryopreserved transiently transfected recombinant cells, the process comprising:

transiently transfecting cells with one or more genes encoding a drug transporter protein to provide the transiently transfected recombinant cells; and

cryopreserving the transiently transfected recombinant cells within 48 hours of transfection, wherein the transient transfection of the cells comprises electroporation;

wherein said one or more genes is OAT3 and wherein said cell is HEK293.

7. The process of claim 6 , wherein the transiently transfected recombinant cells are cryopreserved at 30 minutes to 24 hours post transfection.

8. A cryopreserved transiently transfected recombinant cell prepared according to the process of claim 6 .

Assignments (2)
SECURITY INTEREST Recorded Aug 14, 2025
From: DISCOVERY LIFE SCIENCES, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 072023/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2022
From: CORNING INCORPORATED
To: DISCOVERY LIFE SCIENCES, LLC
Reel/Frame 060197/0485 →
Continuity (5)
Continuation 14972012 · Dec 16, 2015
Division 14644000 · Mar 10, 2015
Continuation PCTUS2013059152 · Sep 11, 2013
Provisional Application 61699466 · Sep 11, 2012
Related Publication 20170355746A1 · Dec 14, 2017